{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "e8f4b317",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import datetime as dt\n",
    "# import wget\n",
    "import zipfile\n",
    "from tqdm import tqdm\n",
    "import pandas as pd\n",
    "import xml.etree.ElementTree as ET\n",
    "import glob\n",
    "import numpy as np\n",
    "import pprint\n",
    "\n",
    "from requests.auth import HTTPBasicAuth,HTTPDigestAuth\n",
    "import requests"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "5a065a2b",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.read_csv('../dataset/cortellis/drug_info_df.csv')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "66b6d907",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(2578, 25)"
      ]
     },
     "execution_count": 6,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.shape"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "2abdb73f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>drug_id</th>\n",
       "      <th>drug_name</th>\n",
       "      <th>drug_synonyms_value</th>\n",
       "      <th>drug_synonyms_type</th>\n",
       "      <th>therapy_areas</th>\n",
       "      <th>drug_primary_action_value</th>\n",
       "      <th>drug_primary_action_id</th>\n",
       "      <th>drug_secondary_action_value</th>\n",
       "      <th>drug_secondary_action_id</th>\n",
       "      <th>drug_primary_indication_value</th>\n",
       "      <th>...</th>\n",
       "      <th>drug_secondary_company_value</th>\n",
       "      <th>drug_secondary_company_id</th>\n",
       "      <th>drug_company_originator_value</th>\n",
       "      <th>drug_company_originator_id</th>\n",
       "      <th>drug_brand_names</th>\n",
       "      <th>drug_generic_names</th>\n",
       "      <th>molecular_mechanism_value</th>\n",
       "      <th>molecular_mechanism_id</th>\n",
       "      <th>cellular_mechanism_value</th>\n",
       "      <th>cellular_mechanism_id</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>100013</td>\n",
       "      <td>asparaginase, Medac</td>\n",
       "      <td>asparaginase, Medac|Spectrila</td>\n",
       "      <td>Trade Name</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Asparaginase stimulator</td>\n",
       "      <td>517</td>\n",
       "      <td>Apoptosis stimulator|Anticancer</td>\n",
       "      <td>1589|1545</td>\n",
       "      <td>Acute lymphoblastic leukemia</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Medac GmbH</td>\n",
       "      <td>17967</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>100057</td>\n",
       "      <td>MRx-518</td>\n",
       "      <td>live biotherapeutic preparation (MicroRx, canc...</td>\n",
       "      <td>Research Code|Research Code</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Microbiome modulator|Immunostimulant|Anticancer</td>\n",
       "      <td>173474|393|1545</td>\n",
       "      <td>Pancreas tumor|Prostate tumor|Stage IV melanom...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>4D pharma plc</td>\n",
       "      <td>1093689</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>100070</td>\n",
       "      <td>naporafenib</td>\n",
       "      <td>LXH-254|pan-RAF inhibitor (oral/tablet, advanc...</td>\n",
       "      <td>Research Code|PINN</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Raf 1 protein kinase inhibitor|Raf B protein k...</td>\n",
       "      <td>4550|4548</td>\n",
       "      <td>Anticancer protein kinase inhibitor</td>\n",
       "      <td>62255</td>\n",
       "      <td>Stage IV melanoma|Metastatic colorectal cancer...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Novartis Pharmaceuticals Corp</td>\n",
       "      <td>24818</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>100109</td>\n",
       "      <td>tirapazamine (hepatocellular carcinoma), Tecli...</td>\n",
       "      <td>tirapazamine|tirapazamine (hepatocellular carc...</td>\n",
       "      <td>USAN|INN</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Bioreducible cytotoxin|Anticancer</td>\n",
       "      <td>1585|1545</td>\n",
       "      <td>Neuroendocrine tumor|Hepatocellular carcinoma|...</td>\n",
       "      <td>...</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>Teclison Ltd</td>\n",
       "      <td>1116794</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>100129</td>\n",
       "      <td>topotecan hydrochloride (oral, small-cell lung...</td>\n",
       "      <td>Hycamtin|topotecan hydrochloride|topotecan|top...</td>\n",
       "      <td>Trade Name|USAN|BAN|INN</td>\n",
       "      <td>Cancer</td>\n",
       "      <td>Topoisomerase I inhibitor</td>\n",
       "      <td>141</td>\n",
       "      <td>Anticancer</td>\n",
       "      <td>1545</td>\n",
       "      <td>Small-cell lung cancer</td>\n",
       "      <td>...</td>\n",
       "      <td>GlaxoSmithKline plc</td>\n",
       "      <td>28355</td>\n",
       "      <td>GlaxoSmithKline plc</td>\n",
       "      <td>28355</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows Ã— 25 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   drug_id                                          drug_name  \\\n",
       "0   100013                                asparaginase, Medac   \n",
       "1   100057                                            MRx-518   \n",
       "2   100070                                        naporafenib   \n",
       "3   100109  tirapazamine (hepatocellular carcinoma), Tecli...   \n",
       "4   100129  topotecan hydrochloride (oral, small-cell lung...   \n",
       "\n",
       "                                 drug_synonyms_value  \\\n",
       "0                      asparaginase, Medac|Spectrila   \n",
       "1  live biotherapeutic preparation (MicroRx, canc...   \n",
       "2  LXH-254|pan-RAF inhibitor (oral/tablet, advanc...   \n",
       "3  tirapazamine|tirapazamine (hepatocellular carc...   \n",
       "4  Hycamtin|topotecan hydrochloride|topotecan|top...   \n",
       "\n",
       "            drug_synonyms_type therapy_areas  \\\n",
       "0                   Trade Name        Cancer   \n",
       "1  Research Code|Research Code        Cancer   \n",
       "2           Research Code|PINN        Cancer   \n",
       "3                     USAN|INN        Cancer   \n",
       "4      Trade Name|USAN|BAN|INN        Cancer   \n",
       "\n",
       "                           drug_primary_action_value drug_primary_action_id  \\\n",
       "0                            Asparaginase stimulator                    517   \n",
       "1                                                NaN                    NaN   \n",
       "2  Raf 1 protein kinase inhibitor|Raf B protein k...              4550|4548   \n",
       "3                                                NaN                    NaN   \n",
       "4                          Topoisomerase I inhibitor                    141   \n",
       "\n",
       "                       drug_secondary_action_value drug_secondary_action_id  \\\n",
       "0                  Apoptosis stimulator|Anticancer                1589|1545   \n",
       "1  Microbiome modulator|Immunostimulant|Anticancer          173474|393|1545   \n",
       "2              Anticancer protein kinase inhibitor                    62255   \n",
       "3                Bioreducible cytotoxin|Anticancer                1585|1545   \n",
       "4                                       Anticancer                     1545   \n",
       "\n",
       "                       drug_primary_indication_value  ...  \\\n",
       "0                       Acute lymphoblastic leukemia  ...   \n",
       "1  Pancreas tumor|Prostate tumor|Stage IV melanom...  ...   \n",
       "2  Stage IV melanoma|Metastatic colorectal cancer...  ...   \n",
       "3  Neuroendocrine tumor|Hepatocellular carcinoma|...  ...   \n",
       "4                             Small-cell lung cancer  ...   \n",
       "\n",
       "  drug_secondary_company_value drug_secondary_company_id  \\\n",
       "0                          NaN                       NaN   \n",
       "1                          NaN                       NaN   \n",
       "2                          NaN                       NaN   \n",
       "3                          NaN                       NaN   \n",
       "4          GlaxoSmithKline plc                     28355   \n",
       "\n",
       "   drug_company_originator_value drug_company_originator_id drug_brand_names  \\\n",
       "0                     Medac GmbH                      17967              NaN   \n",
       "1                  4D pharma plc                    1093689              NaN   \n",
       "2  Novartis Pharmaceuticals Corp                      24818              NaN   \n",
       "3                   Teclison Ltd                    1116794              NaN   \n",
       "4            GlaxoSmithKline plc                      28355              NaN   \n",
       "\n",
       "  drug_generic_names molecular_mechanism_value molecular_mechanism_id  \\\n",
       "0                NaN                       NaN                    NaN   \n",
       "1                NaN                       NaN                    NaN   \n",
       "2                NaN                       NaN                    NaN   \n",
       "3                NaN                       NaN                    NaN   \n",
       "4                NaN                       NaN                    NaN   \n",
       "\n",
       "  cellular_mechanism_value cellular_mechanism_id  \n",
       "0                      NaN                   NaN  \n",
       "1                      NaN                   NaN  \n",
       "2                      NaN                   NaN  \n",
       "3                      NaN                   NaN  \n",
       "4                      NaN                   NaN  \n",
       "\n",
       "[5 rows x 25 columns]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "96113f26",
   "metadata": {},
   "outputs": [],
   "source": [
    "sample_drug = df['drug_id'].sample(1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "61cf704b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "120013"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "sample_drug.iloc[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "8eadaf11",
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "b'<?xml version=\"1.0\" encoding=\"UTF-8\" standalone=\"yes\"?><drugRecordOutput id=\"120013\"><DrugName>ICG-134</DrugName><DrugSynonyms><Name><Value>CD19 CARvac T cells</Value></Name><Name><Value>anti-CD19 CAR T-cell therapy + tumor vaccine (CARvac, B-cell lymphoma/B cell leukemia), iCell Gene Therapeutics/iCAR Bio</Value></Name><Name><Value>ICG-134</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id=\"1124295\">iCell Gene Therapeutics</CompanyOriginator><CompaniesPrimary><Company id=\"1195729\">iCar Bio Therapeutics Ltd</Company><Company id=\"1124295\">iCell Gene Therapeutics</Company></CompaniesPrimary><CrossReferences><SourceEntity id=\"1124295\" type=\"Company\"><TargetEntity id=\"5050988496\" type=\"organizationId\">Icell Gene Therapeutics LLC</TargetEntity></SourceEntity><SourceEntity id=\"1195729\" type=\"Company\"><TargetEntity id=\"5071483129\" type=\"organizationId\">iCAR Bio Therapeutics Ltd</TargetEntity></SourceEntity><SourceEntity id=\"199\" type=\"ciIndication\"><TargetEntity id=\"10024288\" type=\"MEDDRA\"/><TargetEntity id=\"D007938\" type=\"MeSH\"/><TargetEntity id=\"-609576380\" type=\"omicsDisease\"/><TargetEntity id=\"683\" type=\"siCondition\"/></SourceEntity><SourceEntity id=\"316\" type=\"ciIndication\"><TargetEntity id=\"10003899\" type=\"MEDDRA\"/><TargetEntity id=\"-1829786210\" type=\"omicsDisease\"/><TargetEntity id=\"699\" type=\"siCondition\"/></SourceEntity><SourceEntity id=\"1545\" type=\"Action\"><TargetEntity id=\"1937\" type=\"Mechanism\">Anti-TAG-72 (Tumor Associated Glycoprotein 72)</TargetEntity><TargetEntity id=\"4426\" type=\"Mechanism\">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id=\"PTGT-00378\" type=\"ciTarget\"><TargetEntity id=\"8968917199303\" type=\"siTarget\">B-lymphocyte antigen CD19</TargetEntity><TargetEntity id=\"2653\" type=\"omicsTarget\"/></SourceEntity></CrossReferences><PhaseHighest id=\"C1\">Phase 1 Clinical</PhaseHighest><IndicationsPrimary><Indication id=\"199\">Leukemia</Indication><Indication id=\"316\">B-cell lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action id=\"5080\">B-lymphocyte antigen CD19 modulator</Action></ActionsPrimary><ActionsSecondary><Action id=\"1545\">Anticancer</Action><Action id=\"7761\">T-lymphocyte stimulator</Action><Action id=\"12379\">Therapeutic vaccine</Action><Action id=\"393\">Immunostimulant</Action></ActionsSecondary><Technologies><Technology id=\"648\">Intravenous formulation</Technology><Technology id=\"761\">Biological therapeutic</Technology><Technology id=\"1263\">Immuno-oncology</Technology><Technology id=\"1247\">Chimeric antigen receptor T cell therapy</Technology><Technology id=\"740\">Infusion</Technology><Technology id=\"345\">Receptor chimeric</Technology><Technology id=\"84\">Protein fusion</Technology></Technologies><TherapyAreas><TherapyArea>Cancer</TherapyArea></TherapyAreas><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-12-06T13:29:39.000Z</LastModificationDate><ChangeDateLast>2020-02-16T00:00:00.000Z</ChangeDateLast><AddedDate>2019-11-18T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID=\"1124295\" linkType=\"Company\"&gt;iCell Gene Therapeutics&lt;/ulink&gt; and its subsidiary  &lt;ulink linkID=\"1195729\" linkType=\"Company\"&gt;iCAR Bio Therapeutics&lt;/ulink&gt;  are developing \\tICG-134, a CD19 CARvac T cell therapy, comprising T cells genetically engineered  (via lentiviral transduction)  to express chimeric antigen receptors   (CAR) specific for CD19 in combination with a tumor-vaccine effect,   using its CARvac platform, for the potential treatment of  relapsed or refractory B cell malignancies including B cell lymphoma and B cell leukemia    [&lt;ulink linkID=\"2216937\" linkType=\"Reference\"&gt;2216937&lt;/ulink&gt;], [&lt;ulink linkID=\"2195639\" linkType=\"Reference\"&gt;2195639&lt;/ulink&gt;]. In February  2018, an early    phase I study was initiated   [&lt;ulink linkID=\"2216937\" linkType=\"Reference\"&gt;2216937&lt;/ulink&gt;], [&lt;ulink linkID=\"2195639\" linkType=\"Reference\"&gt;2195639&lt;/ulink&gt;]. In November 2019, data from the study were expected in 2H19 [&lt;ulink linkID=\"2195639\" linkType=\"Reference\"&gt;2195639&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2019, an open-labled, single-center, clinical trial (&lt;ulink linkID=\"399219\" linkType=\"Protocol\"&gt;ChiCTR1900026083&lt;/ulink&gt;; SuperCARTRRB1.0) was initiated in China to evaluate the efficacy and safety of &lt;ulink linkID=\"119095\" linkType=\"Drug\"&gt;ICG-132&lt;/ulink&gt;  (CD20/CD19) with ICG-134 (CARvac) in patients (expected n = 24) with relapsed/refractory B cell malignancies; at that time, the trial was expected to complete in November 2021 [&lt;ulink linkID=\"2198091\" linkType=\"Reference\"&gt;2198091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February  2018, an interventional, open-label, single group assignment, single arm, early    phase I study  (&lt;ulink linkID=\"405311\" linkType=\"Protocol\"&gt;NCT04156243&lt;/ulink&gt;; ICG134-001) was initiated in  China to evaluate the safety and tolerability of CD19 CARvac in patients (expected n = 20) with relapsed and/or refractory B cell malignancies. At that time, the trial was expected to complete in February 2020 [&lt;ulink linkID=\"2216937\" linkType=\"Reference\"&gt;2216937&lt;/ulink&gt;]. In September 2019, data from the study were expected in the second half of 2019 [&lt;ulink linkID=\"2195639\" linkType=\"Reference\"&gt;2195639&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;CARvac therapies combine antigen targeting with a tumor-vaccine to prevent cancer relapse due to the loss of target antigen and to overcome immunosupressive tumor microenvironments [&lt;ulink linkID=\"2195639\" linkType=\"Reference\"&gt;2195639&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id=\"1195729\">iCar Bio Therapeutics Ltd</Company><Country id=\"CN\">China</Country><DevelopmentStatus id=\"C1\" sortOrder=\"10\">Phase 1 Clinical</DevelopmentStatus><Indication id=\"316\">B-cell lymphoma</Indication><StatusDate>2018-02-01T00:00:00.000Z</StatusDate><Source id=\"2216937\" type=\"TRIALREG\"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id=\"1195729\">iCar Bio Therapeutics Ltd</Company><Country id=\"CN\">China</Country><DevelopmentStatus id=\"C1\" sortOrder=\"10\">Phase 1 Clinical</DevelopmentStatus><Indication id=\"199\">Leukemia</Indication><StatusDate>2018-02-01T00:00:00.000Z</StatusDate><Source id=\"2216937\" type=\"TRIALREG\"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id=\"1124295\">iCell Gene Therapeutics</Company><Country id=\"CN\">China</Country><DevelopmentStatus id=\"C1\" sortOrder=\"10\">Phase 1 Clinical</DevelopmentStatus><Indication id=\"316\">B-cell lymphoma</Indication><StatusDate>2018-02-01T00:00:00.000Z</StatusDate><Source id=\"2216937\" type=\"TRIALREG\"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id=\"1124295\">iCell Gene Therapeutics</Company><Country id=\"CN\">China</Country><DevelopmentStatus id=\"C1\" sortOrder=\"10\">Phase 1 Clinical</DevelopmentStatus><Indication id=\"199\">Leukemia</Indication><StatusDate>2018-02-01T00:00:00.000Z</StatusDate><Source id=\"2216937\" type=\"TRIALREG\"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id=\"PTGT-00378\"><Name>B-lymphocyte antigen CD19</Name><SwissprotNumbers><Swissprot>P15391</Swissprot><Swissprot>P25917</Swissprot><Swissprot>P25918</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></drugRecordOutput>'"
      ]
     },
     "execution_count": 12,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "url = 'https://api.cortellis.com/api-ws/ws/rs/drugs-v2/drug/' + str(sample_drug.iloc[0])\n",
    "response = requests.get(url, auth=HTTPDigestAuth('bmstrial01','A6HEW41CBIK5PFJ9'))\n",
    "response.content"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "54f4a65e",
   "metadata": {},
   "outputs": [],
   "source": [
    "root = ET.fromstring(response.content)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "504b4714",
   "metadata": {},
   "outputs": [],
   "source": [
    "temp = root.find('DevelopmentProfile')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "5993be3f",
   "metadata": {},
   "outputs": [],
   "source": [
    "# convert xml to nested dictionary, potentially to json\n",
    "class XmlListConfig(list):\n",
    "    def __init__(self, aList):\n",
    "        for element in aList:\n",
    "            if element:\n",
    "                # treat like dict\n",
    "                if len(element) == 1 or element[0].tag != element[1].tag:\n",
    "                    self.append(XmlDictConfig(element))\n",
    "                # treat like list\n",
    "                elif element[0].tag == element[1].tag:\n",
    "                    self.append(XmlListConfig(element))\n",
    "            elif element.text:\n",
    "                text = element.text.strip()\n",
    "                if text:\n",
    "                    self.append(text)\n",
    "\n",
    "\n",
    "class XmlDictConfig(dict):\n",
    "    '''\n",
    "    Example usage:\n",
    "\n",
    "    >>> tree = ElementTree.parse('your_file.xml')\n",
    "    >>> root = tree.getroot()\n",
    "    >>> xmldict = XmlDictConfig(root)\n",
    "\n",
    "    Or, if an XML string:\n",
    "\n",
    "    >>> root = ElementTree.XML(xml_string)\n",
    "    >>> xmldict = XmlDictConfig(root)\n",
    "\n",
    "    '''\n",
    "    def __init__(self, parent_element):\n",
    "        if parent_element.items():\n",
    "            self.update(dict(parent_element.items()))\n",
    "        for element in parent_element:\n",
    "            if element:\n",
    "                # treat like dict - we assume that if the first two tags\n",
    "                # in a series are different, then they are all different.\n",
    "                if len(element) == 1 or element[0].tag != element[1].tag:\n",
    "                    aDict = XmlDictConfig(element)\n",
    "                # treat like list - we assume that if the first two tags\n",
    "                # in a series are the same, then the rest are the same.\n",
    "                else:\n",
    "                    # here, we put the list in dictionary; the key is the\n",
    "                    # tag name the list elements all share in common, and\n",
    "                    # the value is the list itself \n",
    "                    aDict = {element[0].tag: XmlListConfig(element)}\n",
    "                # if the tag has attributes, add those to the dict\n",
    "                if element.items():\n",
    "                    aDict = smart_update(aDict, dict(element.items()))\n",
    "#                     aDict.update(dict(element.items()))\n",
    "#                 self.update({element.tag: aDict})\n",
    "                self = smart_update(self, {element.tag: aDict})\n",
    "            # this assumes that if you've got an attribute in a tag,\n",
    "            # you won't be having any text. This may or may not be a \n",
    "            # good idea -- time will tell. It works for the way we are\n",
    "            # currently doing XML configuration files...\n",
    "            elif element.items():\n",
    "#                 self.update({element.tag: dict(element.items())})\n",
    "                self = smart_update(self, {element.tag: dict(element.items())})\n",
    "            # finally, if there are no child tags and no attributes, extract\n",
    "            # the text\n",
    "            else:\n",
    "#                 self.update({element.tag: element.text})\n",
    "                sel = smart_update(self, {element.tag: element.text})\n",
    "#     @staticmethod\n",
    "#     def smart_update(self, new_dict):\n",
    "#         for key in new_dict.keys():\n",
    "#             if key not in self:\n",
    "#                 self[key] = new_dict[key]\n",
    "#             elif isinstance(self[key], list):\n",
    "#                 self[key].append(new_dict[key])\n",
    "#             else:\n",
    "#                 self[key] = [self[key], new_dict[key]]\n",
    "def smart_update(ori_dict, new_dict):\n",
    "    for key in new_dict.keys():\n",
    "        if key not in ori_dict:\n",
    "            ori_dict[key] = new_dict[key]\n",
    "        elif isinstance(ori_dict[key], list):\n",
    "            ori_dict[key].append(new_dict[key])\n",
    "        else:\n",
    "            ori_dict[key] = [ori_dict[key], new_dict[key]]\n",
    "    return ori_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "e01c92de",
   "metadata": {},
   "outputs": [],
   "source": [
    "xmldict = XmlDictConfig(root)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "57e12858",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'Summary': {'displayLabel': 'Summary',\n",
       "  'value': '<Summary><para><ulink linkID=\"1124295\" linkType=\"Company\">iCell Gene Therapeutics</ulink> and its subsidiary  <ulink linkID=\"1195729\" linkType=\"Company\">iCAR Bio Therapeutics</ulink>  are developing \\tICG-134, a CD19 CARvac T cell therapy, comprising T cells genetically engineered  (via lentiviral transduction)  to express chimeric antigen receptors   (CAR) specific for CD19 in combination with a tumor-vaccine effect,   using its CARvac platform, for the potential treatment of  relapsed or refractory B cell malignancies including B cell lymphoma and B cell leukemia    [<ulink linkID=\"2216937\" linkType=\"Reference\">2216937</ulink>], [<ulink linkID=\"2195639\" linkType=\"Reference\">2195639</ulink>]. In February  2018, an early    phase I study was initiated   [<ulink linkID=\"2216937\" linkType=\"Reference\">2216937</ulink>], [<ulink linkID=\"2195639\" linkType=\"Reference\">2195639</ulink>]. In November 2019, data from the study were expected in 2H19 [<ulink linkID=\"2195639\" linkType=\"Reference\">2195639</ulink>].</para></Summary>'},\n",
       " 'Premarketing': {'displayLabel': 'Premarketing',\n",
       "  'value': '<Premarketing><para>In September 2019, an open-labled, single-center, clinical trial (<ulink linkID=\"399219\" linkType=\"Protocol\">ChiCTR1900026083</ulink>; SuperCARTRRB1.0) was initiated in China to evaluate the efficacy and safety of <ulink linkID=\"119095\" linkType=\"Drug\">ICG-132</ulink>  (CD20/CD19) with ICG-134 (CARvac) in patients (expected n = 24) with relapsed/refractory B cell malignancies; at that time, the trial was expected to complete in November 2021 [<ulink linkID=\"2198091\" linkType=\"Reference\">2198091</ulink>].</para><para>In February  2018, an interventional, open-label, single group assignment, single arm, early    phase I study  (<ulink linkID=\"405311\" linkType=\"Protocol\">NCT04156243</ulink>; ICG134-001) was initiated in  China to evaluate the safety and tolerability of CD19 CARvac in patients (expected n = 20) with relapsed and/or refractory B cell malignancies. At that time, the trial was expected to complete in February 2020 [<ulink linkID=\"2216937\" linkType=\"Reference\">2216937</ulink>]. In September 2019, data from the study were expected in the second half of 2019 [<ulink linkID=\"2195639\" linkType=\"Reference\">2195639</ulink>].</para></Premarketing>'},\n",
       " 'AdditionalInformation': {'displayLabel': 'Additional Information',\n",
       "  'value': '<AdditionalInformation><para>CARvac therapies combine antigen targeting with a tumor-vaccine to prevent cancer relapse due to the loss of target antigen and to overcome immunosupressive tumor microenvironments [<ulink linkID=\"2195639\" linkType=\"Reference\">2195639</ulink>].</para></AdditionalInformation>'}}"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "xmldict['DevelopmentProfile']"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b94ec662",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "conda_pytorch_latest_p36",
   "language": "python",
   "name": "conda_pytorch_latest_p36"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.13"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
